phase readout

NCT07407465: Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

RECRUITINGupdated 1mo ago

community read0 votes

Sponsor: Gruppo Oncologico del Nord-Ovest. Phase: PHASE2. Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma, Rectal Cancer, Metastatic, Colon Cancer Metastatic, Colon Cancer Adenocarcinoma

view source ↗

NCT07407465: Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

comments(0)

Report a data issue